Relationship of oxidative stress and fibrinolysis in diabetes mellitus

Diabetic Medicine

Volumn 13, Issue 9, 1996, Pages 800-805

  Skrha J ^a   Hodinar A ^a   Kvasnicka J ^a   Hilgertova J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Malondialdehyde; Superoxide dismutase; Tissue plasminogen activator

Indexed keywords

MALONALDEHYDE; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS;

ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ERYTHROCYTES; FEMALE; FIBRINOLYSIS; FRUCTOSAMINE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES; REGRESSION ANALYSIS; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0029843142     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199609)13:9<800::AID-DIA178>3.0.CO;2-Q     Document Type: Article

References (41)

1. Wieczorek Y, Pell ACH, McIver B, MacGregor IR, Ludlam CA, Frier BM. Coagulation and fibrinolytic system in type I diabetes: effects of venous occlusion and insulin-induced hypoglycaemia. Clin Sci 1993; 84: 79-86.
2. Gough SCL, Rice PJS, McCormack L, Chapman C, Grant PJ. The relationship between plasminogen activator inhibitor 1 and insulin resistance in newly diagnosed Type 2 diabetes mellitus. Diabetic Med 1993; 10: 638-642.
3. Rydzewski A, Kawamura H, Watanabe I, Takada Y, Takada A. Plasminogen activators and plasminogen activator inhibitor (PAI-1) in Type II diabetes mellitus. Fibrinolysis 1990; 4: 183-188.
4. Kvasnička J, Škrha J. Increase in tissue plasminogen activator (tPA) in relation to microangiopathy in Type I diabetes mellitus. Cor Vasa 1994; 36: 280-285.
5. Garcia Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia Avello A. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 1990; 59: 51-59.
6. Nilsson TK, Boman K, Bjerle P, Hallmans G, Hellsten G. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Int Med 1994; 235: 419-423.
7. Gouch SCI, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabetic Med 1991; 8: 898-905.
8. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-109.
9. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-117.
10. Juhan-Vague I, Vague P, Poisson C, Aillaud MF, Mendez C, Collen D. Effect of 24 hours of normoglycaemia on tissue-type plasminogen activator plasma levels in insulin-dependent diabetes. Thromb Haemostas 1984; 51: 97-98.
11. Juhan-Vague I, Vague P, Alessi MC, Aillaud MF, Collen D. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabete Metab 1991; 13: 331-336.
12. Bahru Y, Kesteven P, Alberti KGMM, Walker M. Decreased plasminogen activator inhibitor-1 activity in newly diagnosed Type 2 diabetic patients following dietary modification. Diabetic Med 1993; 10: 802-806.
13. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemostas 1989; 61: 370-373.
14. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 1994; 43: 426-429.
15. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15: 1835-1843.
16. Dvornik D. Hyperglycemia in the pathogenesis of diabetic complications. In: Dvornik D, Porte D, eds. Aldose Reductase Inhibition. McGraw-Hill, New York, 1987, 73-151.
17. Gallou G, Ruelland A, Legras B, Maugendre D, Allannic H, Cloarec L. Plasma malondialdehyde in type 1 and type 2 diabetic patients. Clin Chim Acta 1993; 214: 227-234.
18. Jos J, Rybak M, Patin PH, Robert JJ, Boitard C, Thevenin R. Etude des enzymes anti-oxidantes dans le diabète insulino-dépendant de l'enfant et de l'adolescent. Diabète Métab 1990; 16: 498-503.
19. Noberasco G, Odetti P, Boeri D, Maiello M, Adezati L. Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycosylated hemoglobin. Biomed Pharmacother 1991; 45: 193-196.
20. Lyons TJ. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Med 1991; 8: 411-419.
21. Jennings PE, Jones AF, Florkowski CM, Lunec J, Barnett AH. Increased diene conjugates in diabetic subjects with microangiopathy. Diabetic Med 1987; 4: 452-456.
22. Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 1982; 127: 87-95.
23. lc by a new liquid-chromatographic assay: methodology, clinical utility and relation to glucose tolerance evaluated. Clin Chem 1986; 32: 1867-1872.
24. Yagi H. A simple fluorimetric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-216.
25. McCord JM, Fridovich I. Superoxide dismutase. J Biol Chem 1969; 244: 6049-6055.
26. Tsuchihashi M. Zur Kenntnis der Blutkatalase. Biochem Z 1923; 40: 63-112.
27. Sato Y, Hotta N, Sakamoto N, Matsuoka S, Ohishi N, Yagi K. Lipid peroxide level in plasma of diabetic patients. Biochem Med 1979; 21: 104-107.
28. Lapenna D, Cuccurullo F. TBA test and 'free' MDA assay in evaluation of lipid peroxidation and oxidative stress in tissue systems (Letter). Am J Physiol 1993; 262: H1030-H1031.
29. Oda A, Bannai C, Yamaoka T, Katori T, Matsushima T, Yamashita K. Inactivation of Cu,Zn-Superoxide dismutase by in vitro glycosylation and in erythrocytes of diabetic patients. Horm Metab Res 1994; 26: 1-4.
30. Kawamura N, Ookawara T, Suzuki K, Konishi K, Mino M, Taniguchi N. Increased glycated Cu,Zn-Superoxide dismutase levels in erythrocytes of patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992; 74: 1352-1354.
31. Gillery P, Monboisse JC, Maquart FX, Borel JP. Does oxygen free radical increased formation explain long term complications of diabetes mellitus? Med Hypotheses 1989; 29: 47-50.
32. Walmsley D, Hampton KK, Grant PJ. Contrasting fibrinolytic responses in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes. Diabetic Med 1991; 8: 954-959.
33. Škrha J, Hodinář A, Kvasnička J, Stibor V, Šperl M, Štolba P, Hilgertová J. Early changes of serum N-acetyl-β-glucosaminidase, tissue plasmingen activator and erythrocyte superoxide dismutase in relation to retinopathy in type 1 diabetes mellitus. Clin Chim Acta 1994; 229: 5-14.
34. Vicari AM, Viganó D'Angelo S, Testa S, Comi C, Galardi G, Orsi E, D'Angelo A. Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus. Horm Metab Res 1992; 24: 516-519.
35. Gunnarson R, Nyman D, Walinder O, Östman J. Fibrinolytic activity and diabetes control - evidence for a relationship. Acta Med Scand 1980; 639 (suppl): 23-24.
36. Škrha J, Vacková I, Kvasnička J, Stibor V, Štolba P, Richter H, Hörmann H. Plasma free N-terminal fibronectin 30-kDa domain as a marker of endothelial dysfunction in type 1 diabetes mellitus. Eur I Clin Invest 1990; 20: 171-176.
37. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetic Med 1993; 10: 27-32.
38. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type 1 in endothelial cells. Diabetes 1992; 41: 890-895.
39. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. Circulation 1994; 89: 321-330.
40. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-1828.
41. Mahmoud R, Raccah D, Alessi MC. Fibrinolysis in insulin dependent diabetic patients with or without nephropathy. Fibrinolysis 1992; 6: 105-109.